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SUMMARY 
 
Alzheimer’s disease is known as the most common form of dementia with an 
increasing number of new cases each year. The promising therapeutic strategy is the 
reduction of neurotoxic Amyloid β (Aβ) fibrils in which aggregation causes AD.  Among 
numerous small molecules investigated as Aβ aggregation modulator, erythrosine B (ER) 
has been shown a safety profile with low toxicity and high blood-brain barrier 
permeability1. Investigation into the mechanism of ER that inhibits the aggregation of Aβ 
was performed using MD simulation. Also by modifying ER into Eosin Y(EOY) and 
Fluorescein (FLN), where halogen was added and removed respectively, the mechanism 
of modified ER was also investigated. From the simulation, binding sites of three 
molecules on Aβ, the effect of the molecules of Aβ’s backbone, and the conformational 
change of Aβ binding residues with the molecules were studied. In conclusion, the results 
showed that halogen plays an important role in binding to Aβ and ER contains the most 
affective structure to inhibit the aggregation of Aβ. 
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CHAPTER 1 
INTRODUCTION 
It is evident from various studies that the most common form of senile dementia, 
Alzheimer’s disease (AD), is due to the accumulation of insoluble protein aggregates, 
composed primarily of neurotoxic Aβ1,2,3. Numerous small molecules have been studied 
for their ability to modulate Aβ aggregation and reduce neurotoxicity 1 . Erythrosine B is 
a well-known food dye approved by FDA and it has been observed that it inhibits the 
formation of Aβ fibril through in vitro experiment.  
 To develop the molecules as future AD therapy, however, further investigation on 
specific chemical molecule structures of Aβ fibril adhered to the molecule is needed. 
From several studies that focused on Aβ fibril destabilization, it was not clear where the 
molecules bind to Aβ and how the binding to the locations promotes its destabilization 1,6. 
Does the adhesion to the small molecules denature the structure of Aβ? Or do the 
molecules bind to a specific terminus of the fibril and prevent the proteins from further 
polymerizing? If so, are the molecules binding to Aβ strong enough to persist for a 
lifetime so that the fibrils would not form ever again?  
Also, it was studied that halogenation of compounds enhance inhibitory capacities 
of small molecules on Aβ –associated neurotoxicity7. Based on the study, it is necessary 
to find an effective molecular structure of small molecules with various modification of 
halogen.  
 The current study attempts to address these questions by investigating the 
mechanism of ER and modified ER on Aβ monomer. The structure of Aβ fibrils binding 
to the destabilizing molecules will be studied in a molecular level using computational 
 2 
modeling with GROMACS 4.6.1. The study investigating the mechanism of ER and its 
modified molecules on Aβ aggregates will lead to helpful results that demonstrate the 
way to improve the candidate drug in terms of efficiency.  
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CHAPTER 2 
LITERATURE REVIEW 
 Although there are some FDA approved drugs that reduce symptoms, successful 
treatment that stops the progression of AD has not yet been developed2. A common 
pathological hallmark of AD is the accumulation of insoluble protein, called amyloid-
beta peptide (Aβ), aggregates in the brain. Significant steps in development of potential 
treatment for AD was to explore how soluble Aβ starts to assemble into amyloid fibrils 
and to find small molecules that effectively reduce toxic Aβ aggregates and cytotoxicity. 
One of the effective modulators is ER, which is a FDA-approved red food dye1. To 
ultimately cure AD with the effective modulators, clarification of how ER can destabilize 
the aggregates and reduce the cytotoxicity is needed. Yang et al., demonstrates the 
exploration of the mechanism for LPFFD, a beta sheet breaker, inhibiting the formation 
of beta sheet conformation of A-beta in water, using several computational models. The 
computational modeling processes in the study can be applied to exploration of ER on 
Aβ. 
The study mainly focuses on exploring how LPFFD inhibits the formation of B-
sheet conformation of Aβ at atomic level.  MD simulation results are analyzed with 
various GROMACS tools. The stability of the complex (LPFFD and amyloid beta) was 
analyzed and confirmed by comparing RMSDs results and the total interaction energies 
between LPFFD and amyloid beta. The extent of hydrophobic burial of different regions 
in the amyloid beta with and without LPFFD was analyzed using SASA (Solvent 
Accessible Surface Area) per residue and it was confirmed that the hydrophobicity of C-
terminal residues decreases with LPFFD and decreased hydrophobicity leads to stable 
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helix structure. By proving that the presence of LPFFD leads to less transition from alpha 
–helix to beta-sheet, the study successfully explored LPFFD’s role as an inhibitor.  
 Through the analysis of molecular docking and MD simulation of LPFFD on the 
Aβ, the study found out several results that support its conclusion; (1) LPFFD binds to 
Aβ (1-42) via hydrogen bonds that stabilize the complex; (2) C-terminus of Aβ no longer 
have conformational change from alpha-helix to beta-sheet with LPFFD; (3) LPFFD 
decreases the hydrophilicity of C-terminus, which helps preventing aggregation of Aβ. 
With these supporting results, the study concluded that LPFFD can inhibit the 
conformational transition from α-helix to β-sheet structure of the C-terminus of Aβ (1-
42).   
The study provides specific computational models to explore the role of LPFFD 
on Aβ and showed the analysis of simulation. The main focus of our research is also 
exploring the mechanism of ER on Aβ to study ER’s molecular characteristics such as 
binding sites on Aβ and the conformational change in Aβ’s backbone, thus the 
computational model applied to the study can be used in our research. 
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CHAPTER 3 
METHODS AND MATERIALS 
MD Simulation 
 To construct molecular structures of Aβ, ER, EOY, and FLN, Cerius 2 was used. 
Jaguar was used to give charge to each molecule, setting B3LYP for functional theory, 6-
31G** for basis, Mulliken for charge analysis, and total charge is -2. With AutoDock, 
binding sites and binding energy of three molecules were found. GROMACS 4.6.1 MD 
package was run for 40ns with force field, GROMOS9653A6. All molecule structures 
were visualized with PyMOL. SPC was used for water, nose-hoover for thermostat, PME 
for electrostatic, and double for precision. 150mM of NaCl is used for simulation 
concentration.  
 
Figure 1. Sequence of Aβ (1-40) extended by Cerius 2 and visualized by PyMOL 
 
Simulation Analysis 
 Root Mean Square Deviation (RMSD) was performed in GROMACS 4.6.1 to see 
the change in the structure of backbone of Aβ. The best-fit line was performed after 
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simulating 80000 ps. To compare conformational difference of Aβ with ER, EOY, and 
FLN, Solvent Accessible Surface Area calculation was done in GROMACS 4.6.1 as well.  
 
Figure 2. Molecular Structure of Eosin Y and Fluorescein modeled by Cerius 2 
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CHAPTER 4 
RESULTS 
Binding sites of ER and modified ER on Aβ 
In order to figure out approximate binding sites of ER, EOY, and FLN on Aβ, 
AutoDock simulation was performed. AutoDock was run three times with three 
combinations; Aβ with ER, Aβ with EOY, and Aβ with FLN. The binding sites were 
obtained with residue numbers, and binding energies of each molecule were calculated as 
well.  
ER had three different binding sites with average binding energy -5.53 kcal/mol. 
EOY is binding to two different residues with average energy -5.95 kcal/mol. FLN 
showed the highest binding energy, -6.65 kcal/mol, with two different binding sites. 
(Figure 3, Table 1).  
 
 
 
 
 
 
Figure 3. Binding sites of ER, EOY, and FLN on Aβ obtained from AutoDock 
simulation. A) Three binding sites of ER on Aβ, B) Two binding sites of EOY on Aβ, C) 
Two binding sites of FLN on Aβ. 
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Molecule Molecule model Binding Energy (kcal/mol) 
ER Brown -5.8 
Pink -5.5 
Green -5.3 
EOY Red -6.0 
Green -5.9 
FLN Pink -6.9 
Brown -6.4 
Table 1. Binding Energy of ER, EOY, and FLN 
 
RMSD Analysis  
 Based on GROMACS simulation done for 40 ns, Root Mean Square Deviations 
(RMSD) of Aβ only, Aβ with ER, Aβ with EOY, and Aβ with FLN were calculated in 
GROMACS and the average value of RMSD for each group are shown in Table 2. Note 
that Aβ only has the lowest value with -6e-6±0.7235 nm and Aβ with ER has the highest 
value with 5e-6±0.7651 nm.  
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Figure 4. RMSD plotted over 8000 ps 
Groups Aβ only (nm) Aβ with ER 
(nm) 
Aβ with FLN 
(nm) 
Aβ with EOY 
(nm) 
RMSD -6E-6±0.7235 5E-6±0.7651 2E-6±0.8635 1E-6±0.6134 
Table 2. RMSD for Aβ only, Aβ with ER, Aβ with FLN, and Aβ with EOY 
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CHAPTER 4 
DISCUSSION 
Data of binding affinities of each molecule obtained by AutoDock shows that Aβ 
with FLN has the highest binding energy compared to Aβ with ER and Aβ with EOY. As 
mentioned above, halogen has high binding affinity to Aβ7. However, FLN that was 
modified by removing all halogen from ER showed higher binding energy with average 
of -6.65 kcal/mol than ER (-5.53 kcal/mol) and EOR (-5.95 kcal/mol) with iodine and 
bromine respectively. This indicates that it may not necessarily mean that having halogen 
increases binding affinity to Aβ.  
 RMSD represents the measure of the average distance between atoms or 
molecules. RMSD analysis was done to see how much three molecules deformed Aβ’s 
backbones by changing the distance between Aβ peptides. The results showed that the 
presence of drug with Aβ showed the positive trend of RMSD but Aβ itself had the 
negative trend. The negative trend indicates that the average distance between the 
monomers is getting closer and Aβ monomers are forming aggregates. On the other hand, 
the positive trend of ER, EOY, and FLN shows that they have increased the distance, 
causing some deformations of the backbone.  
As Figure 4 is shown above, RMSD analysis on Aβ with FLN shows that even 
though the fit line has the positive trend, it is almost constant with a little fluctuation. 
However, Aβ with ER and Aβ with EOY had some fluctuation on the graphs with the 
positive trends. The fact that the overall trend of Aβ with FLN is constant demonstrates 
that FLN molecule does not induce enough deformation of the backbone to inhibit the 
aggregation. Compared to ER and EOY that had iodide and bromine as halogen, FLN 
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was the molecule from which iodide was removed. This proves that halogenation 
enhances inhibitory capacities of the molecules7.  
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CHAPTER 6 
CONCLUSION AND FUTURE WORK 
In this experiment, the investigation has established that ER molecule with 
halogen has more potential of efficient inhibition of Aβ aggregation. The results In case 
of FLN where all halogen were removed, it did not induce significant amount of 
deformation of Aβ, indicating that halogen should be added to small molecules that are 
targeting the Aβ aggregation. Specific residues of Aβ where each molecule binds to are 
important data that can be used to calculate solvent accessible surface area in the future, 
which represents the conformational change of the protein’s residues when interacted 
with the molecules.  
For future study, RMSD analysis should be performed longer than 8000 ps. Even 
though the analysis showed differences on the effects of three molecules on the 
deformation of Aβ, longer simulation would make it possible to verify whether the 
molecules keep deforming the protein over the duration and to investigate the pattern of 
the deformation caused by the molecules as time goes on. Furthermore, to clarify that 
molecules that contain halogen are more capable of inhibiting the aggregates, various 
modifications of halogen in ER structure needs to be studied finding the effective 
structure of ER for the inhibition.  
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